Ivonescimab FDA Approval: What the Complete Response Letter Means

Nov 16, 2026 | Regulatory

Image Source: Generated by Google Gemini
Written by: LSDN Editorial Team
On behalf of: Life Science Daily News

The FDA has declined to approve ivonescimab for EGFR-mutated lung cancer, Summit Therapeutics said on Sunday 15 November 2026. The agency issued a complete response letter, so ivonescimab FDA approval is not in place in this setting. The goal date had been Saturday 14 November. In its release, Summit said the FDA found effectiveness was not established without a statistically significant overall survival gain. This article sets out what is known, what is not, and what could change the outcome.

Can Ivonescimab FDA Approval Still Happen After the Letter?

No US approval is pending today. A complete response letter is not a final refusal. It tells a sponsor what the agency needs before it will approve. Summit had announced no resubmission plan and no new action date as at 16 November 2026. On Summit’s account, the agency’s bar is a statistically significant survival benefit. Any later bid for ivonescimab FDA approval in EGFR-mutated disease would need to meet that bar.

Two routes could change the picture. One is new survival evidence in the same setting. The other is the HARMONi-3 programme, which studies a different setting. Both are covered below.

What the FDA Said in the Complete Response Letter

The FDA’s reasoning below is Summit’s account of the letter. A search on 16 November 2026 found no FDA statement on the decision. Per Summit, the letter says the application “cannot be approved in its present form.” The company says the agency found substantial evidence of effectiveness was not established. That finding rests on the lack of a statistically significant overall survival improvement.

Summit also says the FDA judged progression-free survival alone insufficient. In the agency’s view, as Summit relays it, that benefit does not support a positive benefit-risk profile. The FDA had signalled this position early. Summit’s release of 30 May 2025 said the agency indicated that a statistically significant survival benefit was necessary. Summit submitted its application regardless. The FDA accepted it in January 2026, with a goal date of 14 November 2026.

Robert Duggan, Summit’s chairman and co-chief executive, said the company was disappointed for patients and families. He said the decision did not change Summit’s view of the drug. He pointed to five positive Phase 3 studies across Summit and Akeso. Summit also noted that no FDA-approved regimen in this setting has shown a statistically significant survival benefit.

What the HARMONi Trial Showed

The application for ivonescimab FDA approval rested on HARMONi, a global randomised, double-blind Phase 3 trial (NCT06396065). It enrolled 438 patients with EGFR-mutated non-squamous disease. All had progressed on a third-generation EGFR inhibitor. Patients received ivonescimab or placebo, each with carboplatin and pemetrexed. Progression-free survival and overall survival were both primary endpoints, OncLive reported.

Progression-free survival

The trial met its progression-free survival endpoint. Summit reported a hazard ratio of 0.52 in May 2025. The 95 per cent confidence interval ran from 0.41 to 0.66. Median progression-free survival was 6.8 months on ivonescimab and 4.4 months on placebo, according to OncLive. Objective response was 45 per cent against 34 per cent. Median response duration was 7.6 months against 4.2 months.

Overall survival

The primary survival analysis used an April 2025 data cutoff. Median overall survival was 16.8 months on ivonescimab and 14.0 months on placebo. The hazard ratio was 0.79, with a 95 per cent confidence interval of 0.62 to 1.01. The p value was 0.057, so the result was not statistically significant.

An additional analysis from September 2025 gave a hazard ratio of 0.78. Its confidence interval ran from 0.62 to 0.98. Summit labels the p value of 0.0332 as nominal. A June 2026 update gave a hazard ratio of 0.76. Summit’s July 2026 filing did not give an interval or p value for that figure.

Safety findings

Safety cut both ways. Serious treatment-related adverse events affected 28.0 per cent of patients on ivonescimab and 15.1 per cent on placebo. Grade 3 or higher treatment-related events were 50.0 and 42.2 per cent. Grade 3 or higher decreased platelets were 12.4 and 6.4 per cent. Grade 3 or higher bleeding occurred in fewer than 1 per cent of patients.

Discontinuations for treatment-related events were 7.3 per cent on ivonescimab and 5.0 per cent on placebo. Treatment-related deaths were 1.8 and 2.3 per cent. Summit’s release gives the discontinuation and death figures. The other safety figures come from OncLive’s report of the HARMONi data.

Why the Western Patient Data Matter

HARMONi enrolled patients in Asia, Europe and North America. Western follow-up was short at the primary analysis. Summit said in May 2025 that Western patients had been followed for less time than the median survival. The Western hazard ratio was 0.98 at the primary analysis, with 83 patients on ivonescimab and 82 on placebo. It was 0.84 in September 2025, after 13.7 months of median Western follow-up. Summit reported 0.76 for June 2026, after 23.2 months.

Summit said on 4 November that it had shared the updated analysis with the FDA. Its 15 November release describes the longer follow-up work as post hoc. The company reports a hazard ratio of 0.76 in the full population, in Asian patients and in Western patients. The letter, as Summit describes it, still required a statistically significant survival improvement.

What Could Settle Ivonescimab FDA Approval Next

The next evidence comes from HARMONi-3. It is a Phase 3 trial in first-line non-small cell lung cancer. It compares ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy. Squamous and non-squamous disease are separately powered cohorts. Enrolment is complete in both, according to Summit’s results release of 4 November.

Summit expects the squamous cohort’s primary progression-free survival analysis in the fourth quarter of 2026. An early interim survival analysis is planned alongside it. A further survival interim for that cohort is planned for the first half of 2027. The non-squamous progression-free survival analysis is also expected in the first half of 2027.

Fierce Pharma reported that an earlier squamous interim analysis missed significance on progression-free survival. Summit announced it on 30 April 2026. Summit said the interim carried a higher bar than the final analysis. The independent data monitoring committee recommended continuing the trial.

HARMONi-3 studies a different setting from the rejected application. Its results would inform a separate filing. They would not reverse this letter. On Summit’s account of the letter, a resubmission in EGFR-mutated disease would still need a statistically significant survival result.

What the Letter Means for Summit

Summit held about $629.8 million in cash and short-term investments at 30 September 2026. AstraZeneca completed its $2.0 billion equity investment on 5 October, after the quarter closed. The AstraZeneca investment bought convertible preferred shares. Summit’s results release implies a conversion price of $18.36 per common share.

Summit shares closed at $14.15 on Friday 13 November, down 6.14 per cent on the day, RTTNews reported. That was before the letter became public. Trade outlets reported the shares falling on Monday 16 November. They disagreed on the size of the move, so this article reports direction only.

Ivonescimab is approved in China, where it first gained marketing authorisation in May 2024. Summit’s release says it is not approved in Summit’s licence territories, which include the United States and Europe. The release also states that no PD-1 and VEGF bispecific antibody is approved in the US. Ivonescimab FDA approval would have been a first for the class.

What Remains Unknown

Several points were open as at 16 November 2026. The coverage reviewed that day did not describe a resubmission plan. It did not describe a meeting with the FDA or a new action date. The FDA had not published the letter itself, as far as a search found. Each of these would sharpen the answer to whether ivonescimab FDA approval can follow.

Summit said in its results release that it planned a call after the FDA action. Its confirmation of that call would be the next regulatory signal. The squamous HARMONi-3 analysis in the fourth quarter of 2026 is the next data point. Readers tracking ivonescimab FDA approval should watch both.

    References:
    1. Summit Therapeutics, 2026, “Summit Therapeutics Provides Update Regarding Ivonescimab Biologics License Application (15 November 2026)”. https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Provides-Update-Regarding-Ivonescimab-Biologics-License-Application/default.aspx
    2. Summit Therapeutics, 2026, “Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026 (4 November 2026)”. https://s206.q4cdn.com/652410165/files/doc_news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026-2026.pdf
    3. Summit Therapeutics, Form 8-K, US Securities and Exchange Commission, 2026, “HARMONi overall survival data update (July 2026)”. https://www.sec.gov/Archives/edgar/data/0001599298/000159929826000058/a2026_prx0722xharmonidat.htm
    4. Summit Therapeutics, Business Wire, 2025, “HARMONi topline results release (30 May 2025)”. https://www.businesswire.com/news/home/20250530679531/en
    5. Summit Therapeutics, Business Wire, 2026, “Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application for Ivonescimab in EGFRm NSCLC Post-TKI Therapy (January 2026)”. https://www.businesswire.com/news/home/20260129109846/en/
    All content is published for informational purposes only and does not constitute medical, legal, or investment advice. For more information, see our Terms and Conditions.

    Articles that may be of interest

    Lilly vs Novo in 2026: How the Obesity Market Has Shifted

    Lilly vs Novo in 2026: How the Obesity Market Has Shifted

    Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

    read more

    Articles that may be of interest

    Lilly vs Novo in 2026: How the Obesity Market Has Shifted

    Lilly vs Novo in 2026: How the Obesity Market Has Shifted

    Lilly vs Novo is the rivalry that defines obesity medicine, and 2026 has redrawn the balance between the two companies. Third-quarter results published on 29 October and 4 November show Eli Lilly growing at a scale few drugmakers have reached. Novo Nordisk, meanwhile,...

    read more
    Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

    Zolgensma Tumour Risk: Does the Gene Therapy Cause Tumours?

    Zolgensma tumour risk moved from a label warning to a reported safety signal on 5 November 2026. Novartis said it had received nine tumour reports in treated patients since the 2019 approval. In two cases, the company said, there is evidence that vector DNA integrated...

    read more